Leukemia develops through clonal evolution: a single blood-forming stem cell picks up a genetic change that lets it outgrow its neighbors, and over time its descendants acquire further mutations until they become a full-blown cancer. That same process explains why leukemia can relapse or resist drugs, and it is why modern treatment advances focus on reading each leukemia’s genetic makeup and targeting it directly.
In this article I trace leukemia from its first mutation to diagnosis and treatment, and explain how an understanding of clones has reshaped therapy. Our leukemia guide gives a broader introduction.
What Leukemia Is
Leukemia is a cancer of the blood-forming tissue in the bone marrow. It causes the overproduction of abnormal white blood cells that fail to mature and function properly, while crowding out normal red cells, white cells, and platelets. It is one of several hematological disorders that patients and caregivers may encounter.
Leukemias are classified by speed (acute or chronic) and by the cell line involved (lymphoid or myeloid):
| Type | Cell line | Pace | Typical age group | Hallmark genetic feature |
|---|---|---|---|---|
| Acute lymphoblastic leukemia (ALL) | Lymphoid | Rapid | Mostly children | Varied; some carry BCR-ABL1 |
| Acute myeloid leukemia (AML) | Myeloid | Rapid | Mostly older adults | Varied; FLT3, NPM1, IDH mutations common |
| Chronic lymphocytic leukemia (CLL) | Lymphoid | Slow | Older adults | Deletions such as del(17p) affect prognosis |
| Chronic myeloid leukemia (CML) | Myeloid | Slow, can transform | Adults | Philadelphia chromosome (BCR-ABL1) |
Clonal Evolution: How Leukemia Begins and Changes
Every blood cell descends from hematopoietic stem cells in the marrow. A clone is a group of cells that all descend from one ancestor and share its mutations. Leukemia starts when one stem or progenitor cell acquires a change that gives it a growth advantage.
From First Hit to Cancer
- Founding mutation: an initial change, sometimes present for years, lets a clone expand. In many older adults, small clones with mutations in genes such as DNMT3A or TET2 exist without causing disease, a state called clonal hematopoiesis.
- Additional hits: further mutations block normal maturation or drive rapid division. When enough accumulate, the clone becomes leukemia.
- Branching subclones: as the leukemia grows, different cells gain different mutations. The result is not one uniform cancer but a family of related subclones.
- Selection under treatment: therapy kills sensitive subclones. Any resistant subclone that survives can grow back, causing relapse.
CML is the clearest example of a single driver. The Philadelphia chromosome, a swap between chromosomes 9 and 22, creates the BCR-ABL1 fusion gene. Its protein is a permanently switched-on tyrosine kinase that pushes cells to divide. Our guide to understanding and diagnosing chronic myeloid leukemia covers this in detail.
Causes and Risk Factors
Most leukemias arise from random mutations with no identifiable trigger. Known risk factors include high-dose ionizing radiation, benzene exposure, previous chemotherapy, smoking (for AML), and certain inherited conditions such as Down syndrome. A family link is uncommon but recognized. Researchers have been piecing these factors together for well over a century, as our history of leukemia describes.
Signs and Symptoms
Symptoms mainly reflect the loss of normal blood cells:
- Anemia: fatigue, pale skin, shortness of breath.
- Low normal white cells: frequent or severe infections, fevers.
- Low platelets: easy bruising, nosebleeds, bleeding gums, pinpoint skin spots. These can be mistaken for other bleeding disorders.
- General symptoms: weight loss, night sweats, bone pain, swollen lymph nodes, and an enlarged spleen.
Acute leukemias tend to cause symptoms over days to weeks. Chronic leukemias are often found by chance on a routine blood test.
Diagnosis: Reading the Clone
Diagnosing leukemia today means not only confirming the cancer but mapping its genetic features:
- Complete blood count and blood film: abnormal white counts, blasts, anemia, low platelets.
- Bone marrow aspirate and biopsy: confirms the diagnosis and estimates the proportion of blasts. In general, 20% or more blasts in the marrow or blood defines acute leukemia.
- Flow cytometry: identifies lineage using surface markers.
- Cytogenetics and FISH: detect chromosomal changes such as the Philadelphia chromosome.
- Molecular testing: PCR and next-generation sequencing panels find mutations that guide risk and drug choice.
Newer research methods, including single-cell sequencing, let scientists see how many subclones a leukemia contains and how they relate. These are mainly research tools at present, but they have deepened understanding of why relapse happens.
Measurable Residual Disease
After treatment, sensitive tests can detect tiny numbers of leukemic cells that a microscope would miss. This measurable residual disease (MRD) testing helps doctors judge whether a remission is deep and whether extra treatment, such as a transplant, is needed.
Treatment Advances
Understanding clones has shifted treatment from one-size-fits-all chemotherapy toward precision medicine. Our article on leukemia treatment from diagnosis to advanced strategies covers each option in depth.
- Chemotherapy: remains the backbone for most acute leukemias.
- Tyrosine kinase inhibitors: imatinib and later drugs block BCR-ABL1 and turned CML into a condition most patients live with long-term.
- Mutation-targeted drugs: FLT3 and IDH inhibitors in AML aim at specific driver mutations.
- BCL-2 and BTK inhibitors: venetoclax and BTK inhibitors have changed CLL care, and venetoclax combinations help older adults with AML.
- Immunotherapy: antibodies such as blinatumomab and CAR-T cell therapy attack B-cell ALL, especially after relapse.
- Stem cell transplant: replaces the diseased marrow and adds a donor immune attack on residual leukemia.
Clonal thinking also explains why combinations work: hitting several targets at once leaves fewer escape routes for resistant subclones.
Key Takeaways
- Leukemia arises when a blood stem cell clone accumulates mutations that let it outgrow normal cells.
- Subclones with different mutations explain relapse and drug resistance.
- Diagnosis now includes genetic and molecular testing, which directs treatment.
- Targeted drugs, immunotherapy, MRD monitoring, and transplant have improved outcomes across many leukemia types.
Frequently Asked Questions
What does clonal evolution mean in leukemia?
It describes how leukemia cells descend from one ancestor cell and keep acquiring new mutations over time. Some of those descendants become more aggressive or drug-resistant, which shapes how the disease behaves.
Is clonal hematopoiesis the same as leukemia?
No. Clonal hematopoiesis means a small population of blood cells carries a mutation, often without any effect on blood counts. Only a small minority of people with it go on to develop a blood cancer.
Why does leukemia sometimes come back after remission?
A few resistant cells, often a subclone with different mutations, can survive treatment. Over time they regrow. MRD testing and consolidation treatment aim to find and eliminate them.
Is leukemia inherited?
Most leukemia is not inherited; the mutations arise during a person’s lifetime. A small number of families carry inherited gene changes that raise risk, and doctors may suggest testing when several relatives are affected.
